Pros and cons of treating murine myasthenia gravis with anti-C1q antibody.
To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 microg or 100 microg of anti-C1q Ab or isotype Ab. Treatment with 10 microg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 microg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.
Tüzün
Erdem
E
Department of Microbiology and Immunology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1070, United States.
Li
Jing
J
Saini
S Shamsher
SS
Yang
Huan
H
Christadoss
Premkumar
P
D000818:Animals; D000906:Antibodies / Q000097:blood / Q000494:pharmacology*; D000936:Antigen-Antibody Complex / Q000097:blood; D001402:B-Lymphocytes / Q000473:pathology; D015922:Complement C1q / Q000276:immunology*; D003176:Complement C3 / Q000378:metabolism; D003165:Complement System Proteins / Q000378:metabolism; D005240:Feasibility Studies; D007074:Immunoglobulin G / Q000378:metabolism; D015850:Interleukin-6 / Q000096:biosynthesis*; D007668:Kidney / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D009157:Myasthenia Gravis / Q000276:immunology / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D011950:Receptors, Cholinergic / Q000276:immunology; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000473:pathology*; D014101:Torpedo
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003176:Complement C3; D007074:Immunoglobulin G; D015850:Interleukin-6; D011950:Receptors, Cholinergic; D015922:Complement C1q; D003165:Complement System Proteins